Singapore Clinical Trial: A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with or without Bevacizumab in Comparison to Active Observation with or without Bevacizumab as Maintenance Treatment in Participants with Newly Diagnosed FIGO Stage III/IV Non-Homologous Recombination Deficient Ovarian Cancer

Singapore, Sept. 12 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with or without Bevacizumab in Comparison to Active Observation with or without Bevacizumab as Maintenance Treatment in Participants with Newly Diagnosed FIGO Stage III/IV Non-Homologous Recombination Deficient Ovarian Cancer'. The following are the other relevant details related to the trial:

Therapeutic Area: Oncology (including Haematology-Oncology)

Trial Centre(s): National Cancer Centre National University Hospital

Trial Status: NA

Principal Investigator(s): Dr Jack Chan Dr David Tan Shao Peng

Published by HT Digital Content Services with pe...